Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

Health and Quality of Life Outcomes

Research

Pranav K. Gandhi¹  Sameer R. Ghate¹  Cheng Wang¹  Stephen Sander¹  Chad Moretz²  Shannon L. Reynolds²  Richard Sheer²  Mary E. Costantino²  Srinivas Annavarapu²  George Andrews³ 

[1] Boehringer Ingelheim, Ridgefield, CT, USA;Comprehensive Health Insights, 315 W Market St., 7th Floor, 40202, Louisville, KY, USA;Humana Inc, Louisville, KY, USA;

关键词: Dabigatran;    Warfarin;    Healthcare resource utilization;    Non-valvular atrial fibrillation;   

DOI  :  10.1186/s12955-017-0705-x

 received in 2017-01-04, accepted in 2017-06-14,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundNovel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource utilization (HCRU) and similar total costs. This study expands on previous work by comparing HCRU and costs for patients newly diagnosed with NVAF and newly initiated on dabigatran or warfarin, and is the first study specifically in a Medicare population.MethodsA retrospective matched-cohort study was conducted using data from administrative health care claims during the study period 01/01/2010–12/31/2012. Cox regression analyses were used to compare all-cause risk of first hospitalizations and emergency room (ER) visits. Medical, pharmacy, and total costs per-patient-per-month (PPPM) were compared between dabigatran and warfarin users.ResultsA total of 1110 patients initiated on dabigatran were propensity score-matched with corresponding patients initiated on warfarin. The mean number of hospitalizations (0.92 vs. 1.13, P = 0.012), ER visits (1.32 vs. 1.56, P < 0.01), office visits (21.43 vs. 29.41; P < 0.01), and outpatient visits (10.86 vs. 22.02; P < 0.01) were lower among dabigatran compared to warfarin users. Patients initiated on dabigatran had significantly lower risk of first all-cause ER visits [hazard ratio (HR): 0.84, 95% confidence interval (CI): 0.73–0.98] compared to those initiated on warfarin. Adjusted mean pharmacy costs PPPM were significantly greater for dabigatran users ($510 vs. $250, P < 0.001); however, mean medical costs PPPM ($1912 vs. $1956, P = 0.55) and mean total costs PPPM ($2381 vs. $2183, P = 0.10) were not significantly different compared to warfarin users.ConclusionsDabigatran users had significantly lower HCRU compared to warfarin users. In addition, dabigatran users had lower risk of all-cause ER visits. Despite higher pharmacy costs, the two cohorts did not differ significantly in medical or total all-cause costs.

【 授权许可】

CC BY   
© The Author(s). 2017